Cognition Therapeutics, Inc. (NASDAQ:CGTX) Stock Has Consensus Target Price of $3.33

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has received a consensus rating of “Moderate Buy” from the four analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and three have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $3.33.

Several analysts have issued reports on CGTX shares. HC Wainwright restated a “buy” rating on shares of Cognition Therapeutics in a research report on Thursday, August 13th. Wall Street Zen cut shares of Cognition Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Monday.

Cognition Therapeutics Stock Up 0.1%

Shares of NASDAQ CGTX opened at $0.95 on Friday. Cognition Therapeutics has a 12 month low of $0.55 and a 12 month high of $2.05. The company has a market cap of $90.41 million, a P/E ratio of -5.59 and a beta of 1.79. The business’s 50 day moving average is $1.00 and its two-hundred day moving average is $1.09.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.02. Sell-side analysts expect that Cognition Therapeutics will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Cognition Therapeutics during the second quarter worth $1,451,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Cognition Therapeutics by 11,695.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,060,282 shares of the company’s stock worth $2,781,000 after acquiring an additional 2,042,815 shares during the period. Sigma Planning Corp boosted its position in shares of Cognition Therapeutics by 7.3% during the 2nd quarter. Sigma Planning Corp now owns 362,265 shares of the company’s stock valued at $417,000 after acquiring an additional 24,500 shares in the last quarter. Corient Private Wealth LP bought a new stake in Cognition Therapeutics in the second quarter valued at about $93,000. Finally, Tocqueville Asset Management L.P. acquired a new position in Cognition Therapeutics in the second quarter worth about $369,000. 43.35% of the stock is currently owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as SIGMAR2, a protein believed to play a role in the cellular processes associated with cognitive decline and neurodegeneration.

Cognition Therapeutics’ lead product candidate is CT1812, an orally administered, brain-penetrant small molecule designed to modulate SIGMAR2. The investigational therapy is being evaluated for Alzheimer’s disease and other forms of dementia, including dementia with Lewy bodies.